# Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

> **NCT07014150** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Resectable

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Iparomlimab and Tuvonralimab

## Key facts

- **NCT ID:** NCT07014150
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014150, "Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07014150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*